Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study
Completed
- Conditions
- OsteoarthritisArthritis, Rheumatoid
- Registration Number
- NCT00612885
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The main objective of this PMS study was to monitor and assess the safety of Mobic® intramuscular injection (7.5mg \~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to Mobic® capsule therapy was possible) in Korean patients with osteoarthritis and rheumatoid arthritis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 425
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy assessment by the treating physician up to 3 day Combined efficacy, safety and tolerability assessment by the treating physician up tp 3 day Incidence of adverse events up tp 3 day
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of meloxicam in osteoarthritis and rheumatoid arthritis pain management?
How does meloxicam intramuscular injection compare to oral NSAIDs in RA and OA treatment efficacy?
Which biomarkers correlate with meloxicam response in Korean patients with rheumatoid arthritis?
What adverse event profiles are associated with meloxicam parenteral use in chronic arthritis?
How does meloxicam compare to other COX-2 inhibitors in post-marketing safety surveillance for OA?
Trial Locations
- Locations (1)
Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
Boehringer Ingelheim Investigational Site🇰🇷Seoul, Korea, Republic of